Kari B. Wisinski

Kari B. Wisinski

Oncology
600 Highland Ave
Madison, WI 53792

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications

Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026

Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancer.

Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancer.

Journal: Journal for immunotherapy of cancer
Published: April 07, 2026

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal: Journal of the National Cancer Institute
Published: February 28, 2026

Longitudinal Phenotyping of Circulating Tumor Cells using a Scalable Deep Learning Framework.

Longitudinal Phenotyping of Circulating Tumor Cells using a Scalable Deep Learning Framework.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 10, 2025

Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasis.

Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasis.

Journal: Oncogene
Published: October 26, 2025

Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.

Journal: Cancer research
Published: October 17, 2025

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).

Journal: Cancer research communications
Published: June 06, 2025

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.

Journal: Breast cancer research and treatment
Published: April 04, 2025

Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8+ T Cells in Breast Cancer.

Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8+ T Cells in Breast Cancer.

Journal: Cancers
Published: February 14, 2025

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels.

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels.

Journal: Nature communications
Published: December 17, 2024

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

Journal: Clinical breast cancer
Published: August 14, 2024
Showing 1-12 of 82

Last Updated: 09/26/2026